[Tumor markers in malignant lymphoma].
For malignant lymphoma, there is no highly sensitive or specific tumor marker for diagnosis. However, some tumor markers such as cell surface marker or karyotypic analysis are useful for diagnosis combined with other clinical and pathological information. International Prognostic Index (IPI), Follicular Lymphoma International Prognostic Index (FLIPI), and International Prognostic Score (IPS) are useful to predict prognosis, and utilized to decide therapeutic strategy of aggressive non-Hodgkin's lymphoma (NHL), follicular lymphoma and Hodgkin's lymphoma, respectively. Non-specific biological markers such as soluble interleukin-2 receptor (sIL-2 R) are utilized to evaluate therapeutic effect. In this paper, we describe about the significance of these tumor markers in malignant lymphoma.
Kato
Harumi
H
Dept. of Hematology and Cell Therapy, Aichi Cancer Center, Central Hospital, Nagoya, Japan.
Ogura
Michinori
M
D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000175:diagnosis* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood*; D015996:Survival Rate
D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2